Skip to main content
. Author manuscript; available in PMC: 2026 Jul 22.
Published in final edited form as: Trends Pharmacol Sci. 2025 Jul 22;46(8):722–737. doi: 10.1016/j.tips.2025.06.008

Figure 2: LKB1 deficient tumors have distinct metabolic profiles.

Figure 2:

Schematic summarizing recent findings discussed in this review. Red arrows indicate direction of change in response to LKB1 deficiency. Cartoon pills indicate where drugs under discussion intersect with the indicated pathways. A) Glucose metabolism. B) Mitochondrial metabolism. C) Reactive oxygen species. D) Combination therapies. Abbreviations: HDAC6i, HDAC6 inhibition; GLSi, Glutaminase inhibition; G6PDi, G6PD inhibition; 8-Cl-Ado, 8-chloro-adenosine; and MitoQ, mitoquinol.